Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help
24 results
  1. NLM Digital Collections - Biologic therapies for treatment of asthma associated with type 2 inflammation : ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2018
    resource.nlm.nih.gov/101745064
    ... Report – Biologic Therapies for Treatment of Asthma 18. Regeneron Pharmaceuticals Inc. and Sanofi. Statement at Midwest CEPAC Public ... PhD Senior Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals Representing Sanofi Genzyme/Regeneron Conflicts of Interest: Andreas ...
  2. NLM Digital Collections - Dupilumab and crisaborole for atopic dermatitis : effectiveness and value : final evidence ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, June 8, 2017
    resource.nlm.nih.gov/101723893
    ... IGA 0/1 With concomitant o) • Pruritus NRS Regeneron Pharmaceuticals topical corticosteroids p) Exclusion criteria • BSA • Prior CsA, ... statement. Yufang Lu, Executive Director, Medical Affairs Immunology, Regeneron Pharmaceuticals, Inc. Sanofi Genzyme and Regeneron Pharmaceuticals are proud ...
  3. NLM Digital Collections - Targeted immune modulators for rheumatoid arthritis : effectiveness and value : evidence ... 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
    resource.nlm.nih.gov/101723892
    ... MPA Senior Director of HEOR National Vice President Regeneron Pharmaceuticals Arthritis Foundation Andrew J. Laster, MD, FACR, CCD ... D., Senior Director, Health Economics and Outcomes Research; Regeneron Pharmaceuticals Sanofi-Genzyme and Regeneron would like to reiterate ...
  4. NLM Digital Collections - PCSK9 inhibitors for treatment of high cholesterol : effectiveness, value, and value-based ... 
    Publication: [Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
    resource.nlm.nih.gov/101672684
    ... considered as a class:  Alirocumab (Praluent®, Sanofi and Regeneron Pharmaceuticals, Inc.)  Evolocumab (Repatha™, Amgen) We considered the PCSK9 ... reduce LDL-C levels. Alirocumab (Praluent®, Sanofi and Regeneron Pharmaceuticals, Inc.) Alirocumab is a human monoclonal antibody that ...
  5. NLM Digital Collections - Business of healthcare 
    Publication: [Toronto, Ontario] : Thomson Reuters, 21-December-2020
    resource.nlm.nih.gov/101777194
    ... U.S. has also signed deals with AstraZeneca and Regeneron Pharmaceuticals for their antibody therapies, under Trump administration's Operation Warp Speed program. The deal with Regeneron covers the cost of manufacturing, while the deal ...
  6. NLM Digital Collections - Redesigning practice to improve care delivery : site visit report 
    Publication: Washington, D.C. : National Health Policy Forum, 2006
    resource.nlm.nih.gov/101271357
    ... He subsequently had a postdoctoral ap- pointment at Regeneron Pharmaceuticals before joining a startup biotechnology company as a ...
  7. NLM Digital Collections - Indication-specific pricing of pharmaceuticals in the United States health care system : a ... 
    Publication: Boston, MA : Institute for Clinical and Economic Review, March 2016
    resource.nlm.nih.gov/101704608
    ... A/S; 2015. 21. EYLEA [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; 2015. 22. ZALTRAP [package insert]. Bridgewater, NJ: ...
  8. NLM Digital Collections - FDA oversight 
    Publication: [Toronto, Ontario] : Thomson Reuters, 23-December-2019
    resource.nlm.nih.gov/101762423
    ... Review. The approval of Dupixent was granted to Regeneron Pharmaceuticals. FDA Approves First Treatment For Neuromyelitis Optica Spectrum ...
  9. NLM Digital Collections - FDA oversight 
    Publication: [Toronto, Ontario] : Thomson Reuters, 21-December-2020
    resource.nlm.nih.gov/101777343
    ... or mechanical ventilation. The EUA was issued to Regeneron Pharmaceuticals Inc. FDA Approves First Drug to Treat Rare ...
  10. NLM Digital Collections - Tezepelumab for severe asthma : final report 
    Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 16, 2021
    resource.nlm.nih.gov/9918401086406676
    ... 5 at screening energy expenditure, mean duration of Regeneron Exclusions: moderate to Pharmaceuticals - Current smoking, vaping, tobacco vigorous physical chewing within ...
previous · 1 · 2 · next